Antibody response to Shiga toxins in Argentinean children with enteropathic hemolytic uremic syndrome at acute and long-term follow-up periods

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Fernández Brando, Romina J ^a,b   Bentancor, Leticia V ^a   Mejías, María Pilar ^a,b   Ramos, María Victoria ^a   Exeni, Andrea ^c   Exeni, Claudia ^d   del Carmen Laso, María ^d   Exeni, Ramón ^d   Isturiz, Martín A ^a,b   Palermo, Marina S ^a,b  

^a INST DE INVEST HEMATOLOGICAS   (Argentina)

^b Instituto de Leucemia Experimental ^*  (Argentina)

^c UNIVERSIDAD AUSTRAL   (Argentina)

^d Hospital Municipal Del Niño   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

SHIGA TOXIN; TOXIN ANTIBODY; VEROTOXIN 1; VEROTOXIN 2;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ARGENTINA; ARTICLE; BLOOD SAMPLING; BLOODY DIARRHEA; CHILD; CONTROLLED STUDY; ENDEMIC DISEASE; ENTEROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FEMALE; GASTROENTERITIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PROTEIN EXPRESSION; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; URBAN AREA; WESTERN BLOTTING;

ANTIBODIES; ARGENTINA; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MALE; SEROLOGIC TESTS; SHIGA TOXINS; TIME FACTORS; TREATMENT OUTCOME;

ESCHERICHIA COLI;

EID: 79955727530     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019136     Document Type: Article

References (42)

1. Karmali MA, (1989) Infection by verocytotoxin-producing Escherichia coli. Clin Microbiol Rev 2: 15-38.
2. Karmali MA, Steele BT, Petric M, Lim C, (1983) Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet 1: 619-620.
3. Palermo MS, Exeni RA, Fernandez GC, (2009) Hemolytic uremic syndrome: pathogenesis and update of interventions. Expert Rev Anti Infect Ther 7: 697-707.
4. Karmali MA, (2009) Host and pathogen determinants of verocytotoxin-producing Escherichia coli-associated hemolytic uremic syndrome. Kidney Int Suppl: S4-7.
5. Fraser ME, Fujinaga M, Cherney MM, Melton-Celsa AR, Twiddy EM, et al. (2004) Structure of shiga toxin type 2 (Stx2) from Escherichia coli O157:H7. J Biol Chem 279: 27511-27517.
6. Johannes L, Romer W, (2010) Shiga toxins-from cell biology to biomedical applications. Nat Rev Microbiol 8: 105-116.
7. O'Brien AD, Tesh VL, Donohue-Rolfe A, Jackson MP, Olsnes S, et al. (1992) Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. Curr Top Microbiol Immunol 180: 65-94.
8. Rivas M, Miliwebsky E, Chinen I, Roldan CD, Balbi L, et al. (2006) Characterization and epidemiologic subtyping of Shiga toxin-producing Escherichia coli strains isolated from hemolytic uremic syndrome and diarrhea cases in Argentina. Foodborne Pathog Dis 3: 88-96.
9. Tzipori S, Sheoran A, Akiyoshi D, Donohue-Rolfe A, Trachtman H, (2004) Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome. Clin Microbiol Rev 17: 926-941, table of contents.
10. Head SC, Karmali MA, Roscoe ME, Petric M, Strockbine NA, et al. (1988) Serological differences between verocytotoxin 2 and shiga-like toxin II. Lancet 2: 751.
11. Cornick NA, Jelacic S, Ciol MA, Tarr PI, (2002) Escherichia coli O157:H7 infections: discordance between filterable fecal shiga toxin and disease outcome. J Infect Dis 186: 57-63.
12. Yamada S, Matsushita S, Kai A, Sasaki M, Tsuji A, et al. (1993) Detection of verocytotoxin from stool and serological testing of patients with diarrhea caused by Escherichia coli O157: H7. Microbiol Immunol 37: 111-118.
13. Barrett TJ, Green JH, Griffin PM, Pavia AT, Ostroff SM, et al. (1991) Enzyme linked immunosorbent assays for detecting antibodies to Shiga-like toxin I, Shiga-like toxin II, and Escherichia coli O157:H7 lipopolysaccharide in human serum. Curr Microbiol 23: 189-195.
14. Caprioli A, Luzzi I, Rosmini F, Pasquini P, Cirrincione R, et al. (1992) Hemolytic-uremic syndrome and Vero cytotoxin-producing Escherichia coli infection in Italy. The HUS Italian Study Group. J Infect Dis 166: 154-158.
15. Lopez EL, Diaz M, Grinstein S, Devoto S, Mendilaharzu F, et al. (1989) Hemolytic uremic syndrome and diarrhea in Argentine children: the role of Shiga-like toxins. J Infect Dis 160: 469-475.
16. Reymond D, Karmali MA, Clarke I, Winkler M, Petric M, (1997) Comparison of the western blot assay with the neutralizing-antibody and enzyme-linked immunosorbent assays for measuring antibody to verocytotoxin 1. J Clin Microbiol 35: 609-613.
17. Ludwig K, Karmali MA, Sarkim V, Bobrowski C, Petric M, et al. (2001) Antibody response to Shiga toxins Stx2 and Stx1 in children with enteropathic hemolytic-uremic syndrome. J Clin Microbiol 39: 2272-2279.
18. Bitzan M, Moebius E, Ludwig K, Muller-Wiefel DE, Heesemann J, et al. (1991) High incidence of serum antibodies to Escherichia coli O157 lipopolysaccharide in children with hemolytic-uremic syndrome. J Pediatr 119: 380-385.
19. Kulkarni H, Goldwater PN, Martin A, Bettelheim KA, (2002) Escherichia coli 'O' group serological responses and clinical correlations in epidemic HUS patients. Comp Immunol Microbiol Infect Dis 25: 249-268.
20. Li Y, Frey E, Mackenzie AM, Finlay BB, (2000) Human response to Escherichia coli O157:H7 infection: antibodies to secreted virulence factors. Infect Immun 68: 5090-5095.
21. Karmali MA, Mascarenhas M, Shen S, Ziebell K, Johnson S, et al. (2003) Association of genomic O island 122 of Escherichia coli EDL 933 with verocytotoxin-producing Escherichia coli seropathotypes that are linked to epidemic and/or serious disease. J Clin Microbiol 41: 4930-4940.
22. Serna At, Boedeker EC, (2008) Pathogenesis and treatment of Shiga toxin-producing Escherichia coli infections. Curr Opin Gastroenterol 24: 38-47.
23. Karmali MA, Mascarenhas M, Petric M, Dutil L, Rahn K, et al. (2003) Age-specific frequencies of antibodies to Escherichia coli verocytotoxins (Shiga toxins) 1 and 2 among urban and rural populations in southern Ontario. J Infect Dis 188: 1724-1729.
24. Karmali MA, Petric M, Winkler M, Bielaszewska M, Brunton J, et al. (1994) Enzyme-linked immunosorbent assay for detection of immunoglobulin G antibodies to Escherichia coli Vero cytotoxin 1. J Clin Microbiol 32: 1457-1463.
25. Lopez EL, Diaz M, Devoto S, Grinstein S, Woloj M, et al. (1991) Evidence of infection with organisms producing Shiga-like toxins in household contacts of children with the hemolytic uremic syndrome. Pediatr Infect Dis J 10: 20-24.
26. Capozzo AV, Pistone Creydt V, Dran G, Fernandez G, Gomez S, et al. (2003) Development of DNA vaccines against hemolytic-uremic syndrome in a murine model. Infect Immun 71: 3971-3978.
27. Wen SX, Teel LD, Judge NA, O'Brien AD, (2006) Genetic toxoids of Shiga toxin types 1 and 2 protect mice against homologous but not heterologous toxin challenge. Vaccine 24: 1142-1148.
28. Creydt VP, Miyakawa MF, Martin F, Zotta E, Silberstein C, et al. (2004) The Shiga toxin 2 B subunit inhibits net fluid absorption in human colon and elicits fluid accumulation in rat colon loops. Braz J Med Biol Res 37: 799-808.
29. Yamada S, Kai A, Kudoh Y, (1994) Serodiagnosis by passive hemagglutination test and verotoxin enzyme-linked immunosorbent assay of toxin-producing Escherichia coli infections in patients with hemolytic-uremic syndrome. J Clin Microbiol 32: 955-959.
30. Ludwig K, Bitzan M, Bobrowski C, Muller-Wiefel DE, (2002) Escherichia coli O157 fails to induce a long-lasting lipopolysaccharide-specific, measurable humoral immune response in children with hemolytic-uremic syndrome. J Infect Dis 186: 566-569.
31. Rivas M, Miliwebsky E, Chinen I, Deza N, Leotta GA, (2006) [The epidemiology of hemolytic uremic syndrome in Argentina. Diagnosis of the etiologic agent, reservoirs and routes of transmission]. Medicina (B Aires) 66 (Suppl 3): 27-32.
32. Werber D, Mason BW, Evans MR, Salmon RL, (2008) Preventing household transmission of Shiga toxin-producing Escherichia coli O157 infection: promptly separating siblings might be the key. Clin Infect Dis 46: 1189-1196.
33. Ludwig K, Sarkim V, Bitzan M, Karmali MA, Bobrowski C, et al. (2002) Shiga toxin-producing Escherichia coli infection and antibodies against Stx2 and Stx1 in household contacts of children with enteropathic hemolytic-uremic syndrome. J Clin Microbiol 40: 1773-1782.
34. Rowe PC, Orrbine E, Lior H, Wells GA, McLaine PN, (1993) Diarrhoea in close contacts as a risk factor for childhood haemolytic uraemic syndrome. The CPKDRC co-investigators. Epidemiol Infect 110: 9-16.
35. Rowe PC, Orrbine E, Ogborn M, Wells GA, Winther W, et al. (1994) Epidemic Escherichia coli O157:H7 gastroenteritis and hemolytic-uremic syndrome in a Canadian inuit community: intestinal illness in family members as a risk factor. J Pediatr 124: 21-26.
36. Bitzan M, Ludwig K, Klemt M, Konig H, Buren J, et al. (1993) The role of Escherichia coli O 157 infections in the classical (enteropathic) haemolytic uraemic syndrome: results of a Central European, multicentre study. Epidemiol Infect 110: 183-196.
37. Masana MO, Leotta GA, Del Castillo LL, D'Astek BA, Palladino PM, et al. (2010) Prevalence, characterization, and genotypic analysis of Escherichia coli O157:H7/NM from selected beef exporting abattoirs of Argentina. J Food Prot 73: 649-656.
38. Bitzan M, (2009) Treatment options for HUS secondary to Escherichia coli O157:H7. Kidney Int Suppl: S62-66.
39. Sheoran AS, Chapman S, Singh P, Donohue-Rolfe A, Tzipori S, (2003) Stx2-specific human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants. Infect Immun 71: 3125-3130.
40. Smith MJ, Teel LD, Carvalho HM, Melton-Celsa AR, O'Brien AD, (2006) Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2. Vaccine 24: 4122-4129.
41. Krautz-Peterson G, Chapman-Bonofiglio S, Boisvert K, Feng H, Herman IM, et al. (2008) Intracellular neutralization of shiga toxin 2 by an a subunit-specific human monoclonal antibody. Infect Immun 76: 1931-1939.
42. Lindgren SW, Samuel JE, Schmitt CK, O'Brien AD, (1994) The specific activities of Shiga-like toxin type II (SLT-II) and SLT-II-related toxins of enterohemorrhagic Escherichia coli differ when measured by Vero cell cytotoxicity but not by mouse lethality. Infect Immun 62: 623-631.